Pixantrone was shown to reduce the severity of clinical manifestation in experimental myasthenia gravis. In the present work we further studied its therapeutic effect. Our results demonstrate that a single administration suppressed AChR-specific immune-responses in primed rats. However, clinical symptoms could be improved only by repeated drug administrations (q7dx6 protocol-8.12 mg/kg); this treatment allowed stable serum drug levels for at least 7 days, as assessed by a functional T-cell bioassay. Pixantrone exerted strong in vitro inhibitory effect only on proliferating T-cells without impairing dendritic cell differentiation and B-cell viability. Our data further demonstrate that Pixantrone is a promising immunosuppressant drug that should be investigated in myasthenia gravis.
Introduction
MG is an antibody-mediated disorder in which autoantibodies against the acetylcholine receptors (AChR) activate the complement cascade leading to a numerical and functional loss of AChR at the neuromuscular junction (Fambrough et al., 1973; Heinemann et al., 1977; Kao and Drachman, 1977) . As a consequence, neuromuscular transmission is impaired and patients complain of various degrees of muscle weakness and fatigability. Although the symptoms of MG are mediated primarily by autoantibodies, AChR-specific CD4+ T cells have a crucial role in the pathogenesis of the disease (Karachunski et al., 2000; Im et al., 2001) . Indeed, effector Th1 cells secrete proinflammatory cytokines, such as IFN-γ, and are implicated in the pathogenesis of antibodymediated autoimmune diseases, since IgG synthesis is T-cell dependent (Romagnani, 1997; Weigle and Romball, 1997 ). The EAMG model, characterized by the presence of CD4+ T cells and autoantibodies (IgG1 and 2 types) specific for the AChR (Christadoss et al., 2000; Baggi et al., 2012) , is considered a reliable model for the human disease and is suitable for investigating the pathophysiology of MG as well as novel therapeutic strategies (Souroujon et al., 2010) .
New immunosuppressant drugs are under investigation in preclinical and clinical studies to assess their efficacy on autoimmune diseases. Mitoxantrone (MTX, a synthetic anthracenedione antineoplastic compound) has been approved by the FDA for use in multiple sclerosis (Gonsette, 2007; Conway and Cohen, 2010) . MTX exerts multiple effects on the immune system: suppresses proliferation of T cells, B cells, and macrophages, and impairs antigen presentation by the induction of apoptosis in APCs; moreover, experimental studies showed that also B cell function, antibody production, and transcription of proinflammatory cytokines can be impaired. Nevertheless, MTX shows several side effects, most importantly cardiac dysfunction and altered values in left ventricular ejection fraction, with an increased risk with cumulative doses above 100 mg/m 2 (Ghalie et al., 2002; Cohen and Mikol, 2004) . Acute myeloid leukemia has been also reported (Martinelli et al., 2011) . Pixantrone (PIX) is a novel aza-anthracenedione molecule with antiblastic properties, developed to reduce the cardiotoxic effect of its analog MTX, and so far investigated only in the treatment of non-Hodgkin's lymphomas (Srokowski et al., 2011; Pettengell et al., 2012) . The mechanism of action of PIX is largely unknown but is considered to be similar to that of MTX, since both drugs interact with DNA as intercalants and inhibitors of topoisomerase II (De Isabella et al., 1995) .
The immunosuppressive effect of PIX has been previously investigated in EAE (Cavaletti et al., 2004; Mazzanti et al., 2005) , and we
